X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Asieris Pharma has announced that its product, APL-2301, has been approved for Phase I clinical trials in Australia. It is intended for treating Acinetobacter baumannii infections.
Lead Product(s): APL-2301
Therapeutic Area: Infections and Infectious Diseases Product Name: APL-2301
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 24, 2023
Details:
Cevira (APL-1702) is a photodynamic drug-device combination product in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL), licensed to Asieris by Photocure.
Lead Product(s): APL-1702
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Cevira
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Photocure
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2023
Details:
APL-1401 is an oral drug got IND approval from NMPA for treatment of moderately-to-severely active ulcerative colitis, The IND application had previously been approved by the U.S. Food and Drug Administration.
Lead Product(s): APL-1401
Therapeutic Area: Gastroenterology Product Name: APL-1401
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2023
Details:
In the agreement, Asieris will be utilizing ReviR's innovative RNA modulation Platform Technologies, named BindeR and SpliceR, to identify and develop new therapeutics (SMALL MOLECULES) that target RNA to treat cancer.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Recipient: ReviR Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 07, 2023
Details:
APL-1202 is an orally available reversible MetAP2 Inhibitor with anti-angiogenic, anti-tumor activities and can also modulate tumor immune microenvironment. It is currently in registration clinical trials in China.
Lead Product(s): APL-1202,Tislelizumab
Therapeutic Area: Oncology Product Name: Vesique
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2022
Details:
The study is a randomized, double-blind Phase Ib study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of APL-1401 in patients with moderate to severely active UC.
Lead Product(s): APL-1401
Therapeutic Area: Gastroenterology Product Name: APL-1401
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2022
Details:
SYN117 (nepicastat), is a small molecule drug and the license agreement provides for its development for all non-psychiatric indications and therapeutic uses. The asset has been held by Acorda’s U.S. subsidiary, Biotie Therapies, Inc.
Lead Product(s): Nepicastat
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Acorda Therapeutics
Deal Size: $7.5 million Upfront Cash: $0.5 million
Deal Type: Licensing Agreement August 29, 2022
Details:
APL-1702 (trade name: Cevira®), a drug-device combination photodynamic therapy product for non-surgical treatment of cervical high-grade squamous intraepithelial lesions (HSIL) caused by any HPV subtypes.
Lead Product(s): APL-1702
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Cevira
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2022
Details:
Vesique (APL-1202) is a reversible and orally available MetAP2 inhibitor with anti-angiogenic and anti-tumor activities. Synergistic effects of APL-1202 and tislelizumab have been shown in various model systems of cancer including bladder cancer.
Lead Product(s): APL-1202,Tislelizumab
Therapeutic Area: Oncology Product Name: Vesique
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2022
Details:
APL-1202 is an orally available reversible MetAP2 Inhibitor with anti-angiogenic, anti-tumor activities and can also modulate tumor immune microenvironment. It is currently in Phase III/pivotal clinical trials in China, either as single agent as first-line treatment.
Lead Product(s): APL-1202,Tislelizumab
Therapeutic Area: Oncology Product Name: APL-1202
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: BeiGene
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
